Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Cardinal Health ( (CAH) ) is now available.
On January 13, 2026, Cardinal Health raised its fiscal 2026 non-GAAP diluted earnings per share outlook to at least $10.00, up from a prior range of $9.65 to $9.85, citing strong performance across its five operating segments and signaling continued operational momentum ahead of a detailed update on February 5. The company also projected that its Specialty revenues would exceed $50 billion in fiscal 2026, reflecting a three-year compounded annual growth rate of 16%, underpinned by robust demand in specialty distribution, expansion of its management services organization platforms and more than 30% anticipated revenue growth in BioPharma Solutions, including major new patient-support hub wins such as Sanofi and Regeneron’s Dupixent My Way program. In addition, Cardinal Health reported it had successfully transitioned manufacturer distribution service agreements for all branded drugs affected by the 2026 Medicare Drug Price Negotiation Program before the January 1 implementation, aiming to preserve compensation for its distribution role, and launched the ContinuCare Pathway program within its at-Home Solutions business to streamline medical-benefit diabetes supply delivery through a pharmacy-to-supplier referral model, already adopted by Publix’s nearly 1,400 pharmacies and expanding the program’s reach to more than 11,000 retail and grocery pharmacies. These moves, highlighted during the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, underscore Cardinal Health’s efforts to strengthen its specialty and direct-to-patient platforms while adapting early to U.S. drug pricing reforms, with implications for earnings visibility and competitive positioning across its healthcare distribution and services portfolio.
The most recent analyst rating on (CAH) stock is a Buy with a $244.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.
Spark’s Take on CAH Stock
According to Spark, TipRanks’ AI Analyst, CAH is a Neutral.
Cardinal Health’s overall stock score is driven by strong earnings call performance and robust cash flow management. However, the high P/E ratio and financial leverage concerns weigh on the score. The technical indicators suggest a positive trend, but valuation metrics indicate potential overvaluation. Addressing financial stability and profitability challenges could enhance the stock’s attractiveness.
To see Spark’s full report on CAH stock, click here.
More about Cardinal Health
Cardinal Health is a global healthcare services and products company that distributes pharmaceuticals and specialty products, manufactures and distributes medical and laboratory supplies, supplies home-health and direct-to-patient products and services, operates nuclear pharmacies and manufacturing facilities, and provides performance and data solutions to healthcare providers and other customers.
Average Trading Volume: 2,264,783
Technical Sentiment Signal: Buy
Current Market Cap: $47.78B
See more data about CAH stock on TipRanks’ Stock Analysis page.